HOLIDAY CLOSURES 23/12/21 to 7/1/22
The Practice will be CLOSED from Thursday 23rd December 2021 to Friday 7th January 2022.
Please email us (email@example.com) or leave a voicemail message (1800 246 779) for non-urgent issues.
Existing patients with emergencies or time-critical problems should contact the paging service.
Dr Pras Sivam FRACS (Urol)
Urologist, Uro-Oncologist and Robotic Surgeon
Dr Pras Sivam (Prassannah Satasivam) is a Fellow of the Royal Australasian College of Surgeons and Member of the Society of Urologic Oncology.
Pras grew up in Melbourne and graduated from Haileybury College as Dux of the School in 1998. He joined the University of Melbourne Medical School with a tertiary entrance rank of 99.95. After completing his postgraduate surgical training in Victoria, he accepted a prestigious Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York. This gave him formal training under global leaders in the field of urology. Click here to learn more …
Melbourne Urologist Robotic Prostatectomy Prostate Cancer
Please click below for detailed descriptions of common operations, including robotic prostatectomy, prostate biopsy, vasectomy, stone surgery, TURP and surgery for kidney, bladder and testis cancer.
A unique approach
Dr Pras Sivam’s unique approach to robotic prostatectomy combines elements of both the traditional “anterior” and newer “posterior” techniques. This allows his patients recover continence earlier whilst maintaining excellent cancer control.
Early continence recovery
In a recent audit, we found that 39% of our patients achieved continence (0 pads or 1 security pad) within 2 weeks of surgery, and 65 % within 2 months. Few studies have looked at continence this early after surgery, however one large systematic review reported 3-month continence rates ranging from 25% to 90% (1).
Excellent cancer control
In a recent audit, we achieved superior cancer control rates with a positive margin rate of 0% for organ-confined cancer (stage pT2) and 17% for locally-advanced cancer (stage pT3). For comparison, in one large systematic review the average positive margin rate was 9% for pT2 (range: 4–23%) and 37% for pT3 cancers (range: 29–50%) (2).
(1) Ficarra et al. European Urology, Volume 62 Issue 3, September 2012, Pages 405-417.
(2) Novara et al. European Urology, Volume 62 Issue 3, September 2012, Pages 382-404.